Clinical Trial Update: A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of ABBV-444 artificial tear formulation versus Refresh Optive Unit Dose in adults with Dry Eye Disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Disease

Drugs mentioned

• ABBV-444
• Refresh Optive Unit Dose

Snippet

Sponsor: AbbVie | Conditions: Dry Eye Disease | Phase 3 | Status: RECRUITING